Anahita Ghorbani1, Vijeta Bhambhani2, Robert H Christenson3, Wouter C Meijers4, Rudolf A de Boer4, Daniel Levy5, Martin G Larson6, Jennifer E Ho7. 1. Calhoun Cardiology Center, University of Connecticut Health Center, Farmington, Connecticut. 2. Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts; Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. 3. Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland. 4. Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. 5. National Heart, Lung, and Blood Institute, Boston University's Framingham Heart Study, Framingham, Massachusetts; Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. 6. Framingham Heart Study, Framingham, Massachusetts; Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts. 7. Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts; Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: jho1@mgh.harvard.edu.
Abstract
BACKGROUND: Galectin-3 (Gal-3) has been associated with heart failure (HF) and poor cardiovascular outcomes. However, the effect of longitudinal changes in Gal-3 on clinical outcomes remains unclear. OBJECTIVES: The authors sought to study clinical determinants of change in Gal-3 among community-dwelling individuals. Further, they sought to examine the role of serial Gal-3 measurements in predicting risk of future HF, cardiovascular disease (CVD), and mortality. METHODS: A total of 2,477 participants in the Framingham Heart Study Offspring cohort underwent measurement of plasma Gal-3 levels at 2 examinations (1995 to 1998 and 2005 to 2008). Linear regression models were used to examine clinical correlates of change in Gal-3. Proportional hazards models were used to relate future clinical outcomes with change in Gal-3. RESULTS: The following clinical correlates were associated with greater longitudinal increases in Gal-3 levels: age, female sex, hypertension, diabetes, body mass index, interim development of chronic kidney disease, and HF (p < 0.0001 for all in multivariable model). Change in Gal-3 was associated with future HF (hazard ratio [HR]: 1.39 per 1-SD increase; 95% confidence interval [CI]: 1.13 to 1.71), CVD (HR: 1.29; 95% CI: 1.11 to 1.51), and all-cause mortality (HR: 1.30; 95% CI: 1.17 to 1.46). Change in Gal-3 was associated with both HF with preserved as well as reduced ejection fraction (p < 0.05 for both). CONCLUSIONS: Longitudinal changes in Gal-3 are associated with traditional cardiovascular risk factors and renal disease. In turn, change in Gal-3 predicts future HF, CVD, and mortality in the community. Future studies are needed to determine whether serial Gal-3 measures may be useful in disease prevention.
BACKGROUND:Galectin-3 (Gal-3) has been associated with heart failure (HF) and poor cardiovascular outcomes. However, the effect of longitudinal changes in Gal-3 on clinical outcomes remains unclear. OBJECTIVES: The authors sought to study clinical determinants of change in Gal-3 among community-dwelling individuals. Further, they sought to examine the role of serial Gal-3 measurements in predicting risk of future HF, cardiovascular disease (CVD), and mortality. METHODS: A total of 2,477 participants in the Framingham Heart Study Offspring cohort underwent measurement of plasma Gal-3 levels at 2 examinations (1995 to 1998 and 2005 to 2008). Linear regression models were used to examine clinical correlates of change in Gal-3. Proportional hazards models were used to relate future clinical outcomes with change in Gal-3. RESULTS: The following clinical correlates were associated with greater longitudinal increases in Gal-3 levels: age, female sex, hypertension, diabetes, body mass index, interim development of chronic kidney disease, and HF (p < 0.0001 for all in multivariable model). Change in Gal-3 was associated with future HF (hazard ratio [HR]: 1.39 per 1-SD increase; 95% confidence interval [CI]: 1.13 to 1.71), CVD (HR: 1.29; 95% CI: 1.11 to 1.51), and all-cause mortality (HR: 1.30; 95% CI: 1.17 to 1.46). Change in Gal-3 was associated with both HF with preserved as well as reduced ejection fraction (p < 0.05 for both). CONCLUSIONS: Longitudinal changes in Gal-3 are associated with traditional cardiovascular risk factors and renal disease. In turn, change in Gal-3 predicts future HF, CVD, and mortality in the community. Future studies are needed to determine whether serial Gal-3 measures may be useful in disease prevention.
Authors: Lori B Daniels; Paul Clopton; Gail A Laughlin; Alan S Maisel; Elizabeth Barrett-Connor Journal: Am Heart J Date: 2014-02-18 Impact factor: 4.749
Authors: A Rogier van der Velde; Wouter C Meijers; Jennifer E Ho; Frank P Brouwers; Michiel Rienstra; Stephan J L Bakker; Anneke C Muller Kobold; Dirk J van Veldhuisen; Wiek H van Gilst; Pim van der Harst; Rudolf A de Boer Journal: Heart Date: 2016-04-15 Impact factor: 5.994
Authors: R A de Boer; D J van Veldhuisen; R T Gansevoort; A C Muller Kobold; W H van Gilst; H L Hillege; S J L Bakker; P van der Harst Journal: J Intern Med Date: 2011-11-18 Impact factor: 8.989
Authors: A Rogier van der Velde; Wouter C Meijers; Edwin R van den Heuvel; Stephan J Bakker; Wiek H van Gilst; Pim van der Harst; Hans Hillege; Rudolf A de Boer Journal: Int J Cardiol Date: 2016-07-31 Impact factor: 4.164
Authors: A Rogier van der Velde; Lars Gullestad; Thor Ueland; Pål Aukrust; Yu Guo; Aram Adourian; Pieter Muntendam; Dirk J van Veldhuisen; Rudolf A de Boer Journal: Circ Heart Fail Date: 2013-02-08 Impact factor: 8.790
Authors: Thomas J Wang; Martin G Larson; Daniel Levy; Emelia J Benjamin; Eric P Leip; Torbjorn Omland; Philip A Wolf; Ramachandran S Vasan Journal: N Engl J Med Date: 2004-02-12 Impact factor: 91.245
Authors: John W McEvoy; Yuan Chen; Marc K Halushka; Eric Christenson; Christie M Ballantyne; Roger S Blumenthal; Robert H Christenson; Elizabeth Selvin Journal: J Am Heart Assoc Date: 2016-05-13 Impact factor: 5.501
Authors: Navin Suthahar; Wouter C Meijers; Herman H W Silljé; Jennifer E Ho; Fu-Tong Liu; Rudolf A de Boer Journal: Theranostics Date: 2018-01-01 Impact factor: 11.556
Authors: Roberta Florido; Lucia Kwak; Justin B Echouffo-Tcheugui; Sui Zhang; Erin D Michos; Vijay Nambi; Ronald B Goldberg; Ron C Hoogeveen; Mariana Lazo; Gary Gerstenblith; Wendy S Post; Roger S Blumenthal; Josef Coresh; Aaron R Folsom; Elizabeth Selvin; Christie Ballantyne; Chiadi E Ndumele Journal: J Am Heart Assoc Date: 2022-05-02 Impact factor: 6.106
Authors: Emily S Lau; Aleksandra Binek; Sarah J Parker; Svati H Shah; Markella V Zanni; Jennifer E Van Eyk; Jennifer E Ho Journal: Circ Res Date: 2022-02-17 Impact factor: 23.213
Authors: Mattias Ekström; Anna Hellman; Jan Hasselström; Camilla Hage; Thomas Kahan; Martin Ugander; Håkan Wallén; Hans Persson; Cecilia Linde Journal: ESC Heart Fail Date: 2020-02-19
Authors: Agata Tymińska; Agnieszka Kapłon-Cieślicka; Krzysztof Ozierański; Monika Budnik; Anna Wancerz; Piotr Sypień; Michał Peller; Paweł Balsam; Grzegorz Opolski; Krzysztof J Filipiak Journal: Dis Markers Date: 2019-10-10 Impact factor: 3.434